Mark Exley
Company: Imvax
Job title: Chief Scientific Officer
Seminars:
Goldspire™: A Biologic-Device Combination Immunotherapy that Induces Preclinical Anti-Tumor Responses Against Multiple Solid Tumors Shows Clinical Activity in Glioblastoma 9:30 am
Utilizing a biodiffusion chamber releasing tumor antigens and an IGF1R antisense for effective treatment of glioblastoma Realizing the platform configuration to maximize immunogenic cell death Exploring long-term survival and immunity of glioblastoma patients receiving individualized immunotherapyRead more
day: Conference Day One
Goldspire™: Developing a Fast Turnaround Individualized Cancer Vaccinelike Immunotherapy to Reduce Manufacturing Time & Treat Patients Faster 4:00 pm
Creating an individualized treatment by whole tumor to overcome heterogeneity with the most comprehensive antigens Reducing the personalized cancer vaccine timeline by central manufacturing and optimized logistics Ensuring cGMP cancer vaccine process consistency and quality by using a central manufacture site for alignment with the FDARead more
day: Pre-Conference Focus Day